IGF-1 Concentration Analysis: Technical Principles, Methods, and Applications

IGF-1 concentration analysis is a critical laboratory technique used to quantify insulin-like growth factor 1 in biological samples, serving as the cornerstone for diagnosing and monitoring growth hormone-related disorders such as acromegaly, gigantism, and growth hormone deficiency. This comprehensive technical guide covers sample types, analytical methods including immunoassay and LC-MS/MS, clinical applications, and frequently asked questions to support researchers and clinicians in achieving accurate and reproducible IGF-1 measurement.

Technical Overview

Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid single-chain polypeptide with a molecular weight of approximately 7.6 kDa. It is produced primarily by hepatocytes in response to growth hormone (GH) stimulation and mediates the majority of the anabolic, mitogenic, and growth-promoting effects of GH through binding to the IGF-1 receptor (IGF-1R) on target tissues.

In circulation, more than 99% of IGF-1 is bound to six high-affinity insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), with IGFBP-3 accounting for the majority of the carrier complex. Because IGF-1 concentrations reflect the integrated effect of GH secretion over the preceding 24 to 48 hours and show minimal diurnal variation compared to pulsatile GH, serum IGF-1 measurement is recommended by international consensus guidelines as the first-line biomarker for screening, diagnosis, and therapeutic monitoring of GH-related disorders.

Accurate IGF-1 quantification is analytically challenging due to the presence of IGFBPs, which can interfere with antibody-antigen binding in immunoassays. Consequently, reliable IGF-1 concentration analysis requires careful attention to pre-analytical variables, dissociation of binding proteins, method selection, and age- and sex-specific reference intervals.

Testing Samples

Serum

Serum is the most widely used and recommended sample matrix for IGF-1 concentration analysis. Venous blood is collected into a plain or separator tube, allowed to clot for 30 minutes at room temperature, and centrifuged at 1,500 to 2,000 × g for 10 to 15 minutes. The separated serum should be stored at 2 to 8°C for short-term analysis (up to 48 hours) or frozen at -20°C or below for long-term storage. IGF-1 is relatively stable in serum, and repeated freeze-thaw cycles should be minimized to preserve sample integrity.

Plasma

Plasma collected with EDTA or lithium heparin anticoagulants is an acceptable alternative matrix, particularly when assays have been validated for plasma. Collection tubes should be gently inverted 8 to 10 times immediately after draw, and plasma is separated by centrifugation using the same conditions applied to serum. Citrate plasma may be acceptable if specifically validated by the assay manufacturer.

Dried Blood Spots

Dried blood spot (DBS) sampling is increasingly used in pediatric endocrinology, epidemiological field studies, and sports anti-doping programs due to its minimally invasive collection, ease of transport, and excellent sample stability at ambient temperatures. A small volume of capillary blood is applied to filter paper cards, dried for at least 3 to 4 hours at room temperature, and analyzed after punching and eluting the dried disc. Method-specific validation is essential because hematocrit and spot volume can influence quantitative results.

Testing Items

The core testing items included in IGF-1 concentration analysis are as follows:

• Total IGF-1 concentration, reported in ng/mL or nmol/L (conversion factor: 1 ng/mL = 0.130 nmol/L), representing the sum of free and IGFBP-bound IGF-1 in the circulation.
• Free or bioavailable IGF-1, reflecting the unbound fraction that is biologically active at the tissue level, typically measured in research or specific clinical contexts.
• IGFBP-3 concentration, frequently analyzed alongside IGF-1 to calculate the IGF-1/IGFBP-3 molar ratio, which provides additional information about GH status and protein nutritional state.
• Age- and sex-normalized interpretation, expressed as standard deviation scores (SDS) or percentiles relative to validated reference intervals, which is essential because circulating IGF-1 levels rise during puberty, peak in late adolescence, and decline progressively with age.

Testing Methods

Several analytical platforms are available for IGF-1 quantification, each with distinct advantages and limitations. The most commonly employed methods are described below.

Automated Chemiluminescent Immunoassay (CLIA)

Automated chemiluminescent immunoassays performed on high-throughput immunoanalyzer platforms are the current clinical standard in most hospital laboratories. These sandwich-format assays use capture and detection antibodies directed against distinct IGF-1 epitopes and incorporate acidic or alkaline pretreatment steps to dissociate IGF-1 from IGFBPs, minimizing interference from binding proteins. Key advantages include rapid turnaround time, excellent precision (inter-assay CV typically below 10%), broad dynamic range, and full automation from barcoded sample to reported result.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA provides a cost-effective and accessible option for research laboratories and low-volume testing sites. Competitive or sandwich ELISA kits typically include a sample pretreatment reagent, such as acid-ethanol extraction, to release IGF-1 from the IGFBP-3/ALS ternary complex before immunometric quantification. Although manual ELISA protocols require careful pipetting technique and adherence to incubation times, well-executed assays achieve sensitivity in the low ng/mL range, which is sufficient for the vast majority of clinical and research applications.

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

LC-MS/MS has emerged as a high-accuracy reference method for IGF-1 measurement. Following enzymatic or acid dissociation of binding proteins and proteolytic digestion or immunocapture enrichment, IGF-1 is quantified by monitoring signature peptide transitions in multiple reaction monitoring (MRM) mode using stable isotope-labeled internal standards. This platform offers superior analytical specificity, freedom from antibody cross-reactivity and heterophile antibody interference, and excellent inter-laboratory harmonization, making it particularly valuable for multicenter studies and reference interval establishment.

Radioimmunoassay (RIA)

Historically, IGF-1 was measured by radioimmunoassay following acid-ethanol extraction. While RIA demonstrated acceptable clinical performance, it has largely been superseded by non-isotopic automated methods due to concerns regarding radioactive waste, longer turnaround times, and limited throughput. RIA remains in use in a small number of specialized research laboratories.

Quality Control Considerations

Regardless of the analytical platform employed, a robust quality assurance program is indispensable for reliable IGF-1 concentration analysis:

• Include at least two levels of quality control materials (low and high IGF-1 concentration) in every analytical run, with acceptance criteria based on established Westgard rules.
• Participate in external quality assessment (EQA) or proficiency testing schemes to monitor inter-laboratory comparability and address method-specific bias.
• Verify sample integrity before analysis; grossly hemolyzed, lipemic, or icteric specimens should be rejected or flagged according to validated hemolysis interference limits.
• Apply validated, method-specific age- and sex-adjusted reference intervals, as absolute cutoff values are not transferable between different assay platforms.

Applications

IGF-1 concentration analysis supports a broad spectrum of clinical diagnostic, therapeutic monitoring, and research applications:

• Diagnosis and post-treatment monitoring of acromegaly: elevated serum IGF-1 is a diagnostic criterion, and normalization of IGF-1 is a primary biochemical treatment endpoint following surgery, somatostatin analog therapy, or GH receptor antagonist administration.
• Evaluation of growth hormone deficiency (GHD): abnormally low age-adjusted IGF-1 supports the diagnosis and guides the decision to proceed with dynamic GH stimulation testing in both pediatric and adult patients.
• Investigation of short stature and growth disorders in children: IGF-1 measurement, often combined with IGFBP-3 and bone age assessment, helps differentiate GH-related causes from constitutional or systemic causes of impaired growth.
• Detection of GH abuse in anti-doping programs: IGF-1, together with the GH-2000 marker approach involving IGF-1 and P-III-NP, is used by World Anti-Doping Agency (WADA)-accredited laboratories to identify recombinant GH misuse in athletes.
• Assessment of nutritional and metabolic status: IGF-1 is a sensitive marker of protein-energy malnutrition, hepatic synthetic function, and catabolic illness, as hepatic IGF-1 production is strongly influenced by nutrient intake and insulin levels.
• Pharmaceutical and biomedical research: IGF-1 quantification is integral to pharmacokinetic studies of GH and IGF-1 analog therapies, longitudinal aging research, oncology studies examining the IGF axis, and toxicology assessments.

FAQ

Why do IGF-1 reference ranges vary by age and sex?

Circulating IGF-1 concentrations follow a characteristic physiological trajectory: levels are low at birth, rise progressively through childhood, peak during pubertal development when values may reach two to three times adult levels, and then decline steadily with advancing age. Sex differences and pubertal timing further modulate this pattern. Therefore, laboratory results must always be interpreted against method-specific, age- and sex-stratified reference intervals, ideally expressed as standard deviation scores rather than absolute cutoff values.

How is interference from IGF-binding proteins eliminated?

Because more than 99% of circulating IGF-1 is bound to IGFBPs, virtually all quantitative methods incorporate a pretreatment step to release IGF-1 from its carrier proteins before measurement. Common approaches include acid-ethanol extraction, acidic buffer dissociation, or alkaline surfactant treatment, depending on the assay format. Mass spectrometric methods achieve this through acid dissociation combined with proteolytic digestion or immunocapture. Validated pretreatment is essential to ensure complete release and accurate recovery of total IGF-1.

What is the difference between total and free IGF-1?

Total IGF-1 represents the entire circulating pool, both free and bound, and is the standard clinical measurement used for diagnosing GH disorders. Free IGF-1 refers to the small, unbound, biologically active fraction with a short circulating half-life. Free IGF-1 measurement is analytically more demanding and is primarily used in research settings to study IGF axis physiology or specific conditions such as insulin resistance and extreme IGFBP perturbations.

How stable are samples for IGF-1 analysis?

IGF-1 is one of the more stable peptide hormones in stored specimens. Serum or plasma remains suitable for analysis for up to 24 to 48 hours at 2 to 8°C, several months at -20°C, and years at -70°C or below. Dried blood spots remain stable for weeks at ambient temperature when protected from moisture and excessive heat. Nonetheless, repeated freeze-thaw cycles should be avoided, and samples should be thawed only once prior to analysis.

Can medications or clinical conditions affect IGF-1 results?

Yes. Recombinant GH therapy, oral estrogens, corticosteroids, and certain agents used in acromegaly treatment can significantly alter circulating IGF-1. Systemic conditions including hepatic insufficiency, malnutrition, poorly controlled diabetes, hypothyroidism, and severe inflammatory illness can lower IGF-1 independent of GH status. A thorough medication history and clinical context should accompany every specimen submission to support correct interpretation.

What analytical sensitivity is required for clinical IGF-1 testing?

Typical adult serum IGF-1 concentrations range from approximately 100 to 400 ng/mL, but pediatric and deficient states may yield values below 20 ng/mL. An assay with a limit of quantification of 10 ng/mL or lower is therefore sufficient for essentially all clinical scenarios, and modern CLIA, ELISA, and LC-MS/MS platforms routinely meet or exceed this requirement.